InnoPharmax Balance Sheet Health
Financial Health criteria checks 5/6
InnoPharmax has a total shareholder equity of NT$475.5M and total debt of NT$11.5M, which brings its debt-to-equity ratio to 2.4%. Its total assets and total liabilities are NT$524.2M and NT$48.6M respectively.
Key information
2.4%
Debt to equity ratio
NT$11.50m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$139.66m |
| Equity | NT$475.55m |
| Total liabilities | NT$48.65m |
| Total assets | NT$524.20m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 4172's short term assets (NT$189.0M) exceed its short term liabilities (NT$33.9M).
Long Term Liabilities: 4172's short term assets (NT$189.0M) exceed its long term liabilities (NT$14.7M).
Debt to Equity History and Analysis
Debt Level: 4172 has more cash than its total debt.
Reducing Debt: 4172's debt to equity ratio has increased from 0% to 2.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4172 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4172 has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 8.9% each year.